SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
50403Patients were assigned drug regimens at random. The protocols were different soA.J. Mullen-10/30/2018
50402<I'm just saying that you don't have all that many situations where aMiljenko Zuanic-10/30/2018
50401<In the meantime, it kept the price high if insiders wish to sell lol> YuMiljenko Zuanic-10/30/2018
50400FGEN -- That report from CITI shows only one thing – an unusual buying opportuniArt Bechhoefer-10/30/2018
50399CITI $FGEN We spoke with FGEN mgmt about our note Alert: FGEN: Negative Trend onscott mcdowell110/30/2018
50398Tx, i agree and that made me feel better lollinhtu-10/30/2018
50397Having been an investor for over 60 years, of which the last 35 have been as a rArt Bechhoefer-10/30/2018
50396Two deaths in a dialysis trial of this size are basically noise. I actually addeBiomaven110/30/2018
50395I like FGEN. But -- broadly speaking -- I think you are putting too much stocglass 0.5 full-10/30/2018
50394I remember Peter brought up the possibility of these exact events ie deaths a whlinhtu-10/30/2018
50393My statistics are surely rusty, but I'm a little surprised that number of deatticus4paws110/30/2018
50392Roxadustat does not compare well by those measures - deaths and drugs-related wiA.J. Mullen-10/30/2018
50391Headline from Citi's note... Alert: Negative Trend on Cardiac Events and Dbiocqr110/30/2018
50390I also added to my FGEN position for the following reasons: 1. Company has issuArt Bechhoefer-10/30/2018
50389Apparently Citi thinks it saw adverse cardiac effects in the Asian data. Some haRobohogs-10/30/2018
50388FGEN > Traders Buy High Volume of FibroGen Call Options theenterpriseleaderbiocqr-10/30/2018
50387I was just about to ask if it might be a buy again at this level...nigel bates-10/30/2018
50386FGEN > link to China/Japan posters... dropbox.combiocqr310/30/2018
50385FGEN: There was mention on Twitter of a negative Citi report. TwitterDaveAu-10/29/2018
50384I just gritted my teeth and added.linhtu-10/29/2018
50383Peter FGEN has not suffered any fundamental setbacks to my knowledge recently. Echris714-10/29/2018
50382That's another example of potentially good news for roxadustat and similar dArt Bechhoefer-10/29/2018
50381FGEN - have always wondered whether drug would be good for heart attack patientssemi_infinite -10/29/2018
50380How an outsider in Alzheimer’s research bucked the prevailing theory — and clawebiocqr-10/29/2018
50379FibroGen's roxadustat successful in China studies in CKD-associated anemia OA.J. Mullen110/26/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News